首页> 外文OA文献 >Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

【2h】

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

机译：从参考Etanercept切换到SDZ ETN，依尼易到生物酸，不影响肠道患者中度至重度的类风湿性关节炎患者的疗效，安全性和免疫原性：III期的48周结果，随机，双盲率研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Janusz Jaworski; Marco Matucci-Cerinic; Hendrik Schulze-Koops; Maya H. Buch; Eugeniusz J. Kucharz; Yannick Allanore; Arthur Kavanaugh; Philip Young; Goran Babic;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study [J] . Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, Arthritis research & therapy. . 2019,第1期

机译：从参考依那西普转向依那西普生物仿制药SDZ ETN不会影响依那西普在中度至重度类风湿性关节炎患者中的功效，安全性和免疫原性：III期，随机，双盲EQUIRA研究的48周结果
2. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study [J] . Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, Arthritis research & therapy. . 2019,第1期

机译：使用依那西普生物仿制药（LBEC0101）或从参比依那西普改用LBEC0101对类风湿关节炎患者的长期疗效，安全性和免疫原性：III期多中心，随机，双盲，平行组研究的开放标签扩展
3. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study [J] . Min-Chan Park, Hiroaki Matsuno, Jinseok Kim, Arthritis research & therapy. . 2019,第1期

机译：使用依那西普生物仿制药（LBEC0101）或从参比依那西普改用LBEC0101对类风湿关节炎患者的长期疗效，安全性和免疫原性：III期多中心，随机，双盲，平行组研究的开放标签扩展
4. Switch from reference etanercept to SDZ ETN an etanercept biosimilar does not impact efficacy safety and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III randomized double-blind EQUIRA study [O] . Janusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, 2019

机译：从参考依那西普转向依那西普生物仿制药SDZ ETN不会影响依那西普在中度至重度类风湿关节炎患者中的功效安全性和免疫原性：III期随机双盲EQUIRA研究的48周结果
5. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study [O] . Marco Matucci-Cerinic, Yannick Allanore, Arthur Kavanaugh, 2018

机译：GP2015的疗效，安全性和免疫原性，依赖伊萨普生物仿制性，与中度至重度类风湿性关节炎患者的参考葡萄酒相比：比较期III，随机，双盲率研究的24周结果

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

著录项

引文网络

相似文献

相关主题

期刊订阅